To obtain a prophylactic or therapeutic agent for systemic inflammatory reaction syndrome such as shock and adult respiratory distress syndrome, excellent in pharmacodynamic effects and safety without accompanying side effects by using a specific chromanol glycoside as an active ingredient.
This prophylactic or therapeutic agent contains a chromanol glycoside of the formula [R1 to R4 are each H or a lower alkyl; R5 is H, a lower alkyl or a lower acyl; X is a (substituted)monosaccharide residue or an oligosaccharide residue; n is 0-6; m is 1-6], e.g. 2-(α-D-glucopyranosyl) methyl-2,5,7,8-tetrainethylchroman-6-ol as an active ingredient. Preferably, the daily dose of the active ingredient of the agent is 0.1-10,000 mg/kg body weight in the case of oral administration, and the prophylactic or therapeutic agent is an aqueous preparation.
YOSHIKAWA TOSHIICHI
YOSHIDA NORIMASA
YOSHIKAWA TOSHIICHI